论文部分内容阅读
目的:研究缬沙坦在治疗心血管疾病的临床效果并进行评价。方法:以2008年3月~2009年3月在我院进行治疗的180名心血管疾病患者,随机均分为研究组和对照组,其中对照组只进行最常规基础的治疗方式,研究组在常规治疗的基础上让患者服用缬沙坦,持续治疗一段时间后,观察两组患者的临床表现,比如血压和患者的满意程度,对治疗效果进行对比评价。结果:经治疗后,两组患者的收缩压和舒张压都得到了良好的改善和控制,差异并不悬殊,P>0.05,无统计学意义。经治疗后,据预后统计用缬沙坦进行治疗的研究组仅有3例复发心血管疾病,发病率为3.29%,只进行常规基础治疗的对照组共有15例患者复发,发病率为16.59%,由此可见,研究组的复发率明显低于对照组,差异明显,具有统计学意义(P<0.05)。结论:缬沙坦可以有效地对血管扩容,降低心血管疾病的发生率,因此在基本治疗的基础上用缬沙坦可以有效地控制心血管疾病的复发,这种方式值得在临床上广泛推广。
Objective: To study and evaluate the clinical effect of valsartan in the treatment of cardiovascular diseases. Methods: One hundred and eighty patients with cardiovascular disease who were treated in our hospital from March 2008 to March 2009 were randomly divided into study group and control group, of which the control group only performed the most conventional basic treatment. On the basis of routine treatment, patients were given valsartan, continuous treatment for a period of time, observe the clinical manifestations of patients in two groups, such as blood pressure and patient satisfaction, the comparative evaluation of the treatment effect. Results: After treatment, the systolic and diastolic blood pressure of both groups were well improved and controlled, the difference was not significant, P> 0.05, no statistical significance. After treatment, according to the prognostic statistics with valsartan treatment group only 3 cases of recurrent cardiovascular disease, the incidence was 3.29%, only the routine basic treatment of the control group, a total of 15 patients relapse, the incidence was 16.59% , We can see that the study group’s recurrence rate was significantly lower than the control group, the difference was significant, with statistical significance (P <0.05). Conclusion: Valsartan can effectively vasodilator and reduce the incidence of cardiovascular disease, so based on the basic treatment of valsartan can effectively control the recurrence of cardiovascular disease, this approach deserves to be widely clinically .